Item 8.01. Other Events.

On January 18, 2023, Bellerophon Therapeutics, Inc. issued a press release announcing the completion of enrollment in the Phase 3 REBUILD study for INOpulse® in fibrotic interstitial lung disease. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.



.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits:

Exhibit No.    Description
  99.1           Press Release dated January 18, 2023
104            Cover Page Interactive Data File (Formatted as Inline XBRL)


                                       2

© Edgar Online, source Glimpses